Gout

​The Division of Rheumatology strives to understand more about gout through research.  Please see the list below, which summarizes the studies available to individuals interested in advancing our understanding and treatment of rheumatic disease. 

​Study Name/IRB​#/PIBrief Description​Basic Eligibility​ CriteriaContact​

HORIZON

#20234982

Christopher Striebich, MD, PhD
A Phase 4, Randomized, Double-blind, Multicenter Non-inferiority Trial Evaluating the Efficacy and Safety of Intravenous KRYSTEXXA® (pegloticase) Administered Every 4 Weeks Compared with KRYSTEXXA Administered Every 2 Weeks with Co-administration of Weekly Doses of Methotrexate, Followed by an Open-label Extension, in Participants with Uncontrolled Refractory Gout (FORWARD II)
  1. Adult men or women ≥ 18 years of age
  2. Symptoms of gout including at least one of the following: a)  Presence of at least 1 tophus.  b) Recurrent flares. c) Presence of chronic gouty arthritis.
  3. Willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the trial.

Chong Pedrick

303-724-7518

or

Najeeb Arishi

303-724-7512

 

 

Rheumatology (SOM)

CU Anschutz

Barbara Davis Center for Diabetes

1775 North Aurora Court

3102

Aurora, CO 80045


303-724-7605

CMS Login